These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8307187)

  • 1. Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes.
    Andreasen PA; Sottrup-Jensen L; Kjøller L; Nykjaer A; Moestrup SK; Petersen CM; Gliemann J
    FEBS Lett; 1994 Feb; 338(3):239-45. PubMed ID: 8307187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epithelial glycoprotein-330 mediates endocytosis of plasminogen activator-plasminogen activator inhibitor type-1 complexes.
    Moestrup SK; Nielsen S; Andreasen P; Jørgensen KE; Nykjaer A; Røigaard H; Gliemann J; Christensen EI
    J Biol Chem; 1993 Aug; 268(22):16564-70. PubMed ID: 8344937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes.
    Nykjaer A; Petersen CM; Møller B; Jensen PH; Moestrup SK; Holtet TL; Etzerodt M; Thøgersen HC; Munch M; Andreasen PA
    J Biol Chem; 1992 Jul; 267(21):14543-6. PubMed ID: 1378833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low density lipoprotein receptor-related protein and gp330 bind similar ligands, including plasminogen activator-inhibitor complexes and lactoferrin, an inhibitor of chylomicron remnant clearance.
    Willnow TE; Goldstein JL; Orth K; Brown MS; Herz J
    J Biol Chem; 1992 Dec; 267(36):26172-80. PubMed ID: 1464627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor.
    Nykjaer A; Kjøller L; Cohen RL; Lawrence DA; Garni-Wagner BA; Todd RF; van Zonneveld AJ; Gliemann J; Andreasen PA
    J Biol Chem; 1994 Oct; 269(41):25668-76. PubMed ID: 7929271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
    Rodenburg KW; Kjoller L; Petersen HH; Andreasen PA
    Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. gp330 on type II pneumocytes mediates endocytosis leading to degradation of pro-urokinase, plasminogen activator inhibitor-1 and urokinase-plasminogen activator inhibitor-1 complex.
    Stefansson S; Kounnas MZ; Henkin J; Mallampalli RK; Chappell DA; Strickland DK; Argraves WS
    J Cell Sci; 1995 Jun; 108 ( Pt 6)():2361-8. PubMed ID: 7673355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the binding of pro-urokinase and urokinase-plasminogen activator inhibitor-1 complex to the low density lipoprotein receptor-related protein using a Fab fragment selected from a phage-displayed Fab library.
    Horn IR; Moestrup SK; van den Berg BM; Pannekoek H; Nielsen MS; van Zonneveld AJ
    J Biol Chem; 1995 May; 270(20):11770-5. PubMed ID: 7538122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specificity of serine proteinase/serpin complex binding to very-low-density lipoprotein receptor and alpha2-macroglobulin receptor/low-density-lipoprotein-receptor-related protein.
    Kasza A; Petersen HH; Heegaard CW; Oka K; Christensen A; Dubin A; Chan L; Andreasen PA
    Eur J Biochem; 1997 Sep; 248(2):270-81. PubMed ID: 9346278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low density lipoprotein receptor-related protein is necessary for the internalization of both tissue-type plasminogen activator-inhibitor complexes and free tissue-type plasminogen activator.
    Orth K; Willnow T; Herz J; Gething MJ; Sambrook J
    J Biol Chem; 1994 Aug; 269(33):21117-22. PubMed ID: 8063731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
    Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
    J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor.
    Orth K; Madison EL; Gething MJ; Sambrook JF; Herz J
    Proc Natl Acad Sci U S A; 1992 Aug; 89(16):7422-6. PubMed ID: 1502153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocytosis of urokinase-plasminogen activator inhibitor type 1 complexes bound to a chimeric transmembrane urokinase receptor.
    Li H; Kuo A; Kochan J; Strickland D; Kariko K; Barnathan ES; Cines DB
    J Biol Chem; 1994 Mar; 269(11):8153-8. PubMed ID: 7510679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator.
    Bu G; Williams S; Strickland DK; Schwartz AL
    Proc Natl Acad Sci U S A; 1992 Aug; 89(16):7427-31. PubMed ID: 1502154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential regulation of urokinase-type-1 inhibitor complex endocytosis by phorbol esters in different cell lines is associated with differential regulation of alpha 2-macroglobulin receptor and urokinase receptor expression.
    Kjøller L; Simonsen AC; Ellgaard L; Andreasen PA
    Mol Cell Endocrinol; 1995 Apr; 109(2):209-17. PubMed ID: 7664984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of determinants involved in binding of tissue-type plasminogen activator-plasminogen activator inhibitor type 1 complexes to HepG2 cells.
    Morton PA; Owensby DA; Wun TC; Billadello JJ; Schwartz AL
    J Biol Chem; 1990 Aug; 265(24):14093-9. PubMed ID: 2167306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low density lipoprotein receptor-related protein modulates the expression of tissue-type plasminogen activator in human colon fibroblasts.
    Hardy MM; Feder J; Wolfe RA; Bu G
    J Biol Chem; 1997 Mar; 272(10):6812-7. PubMed ID: 9045716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Degradation of urokinase plasminogen activator (UPA) in endometrial stromal cells requires both the UPA receptor and the low-density lipoprotein receptor-related protein/alpha2-macroglobulin receptor.
    Casslén B; Gustavsson B; Angelin B; Gåfvels M
    Mol Hum Reprod; 1998 Jun; 4(6):585-93. PubMed ID: 9665342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas.
    Christensen L; Wiborg Simonsen AC; Heegaard CW; Moestrup SK; Andersen JA; Andreasen PA
    Int J Cancer; 1996 May; 66(4):441-52. PubMed ID: 8635858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasminogen activator inhibitor-1 and vitronectin promote the cellular clearance of thrombin by low density lipoprotein receptor-related proteins 1 and 2.
    Stefansson S; Lawrence DA; Argraves WS
    J Biol Chem; 1996 Apr; 271(14):8215-20. PubMed ID: 8626514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.